NO20031673L - Behandling av kreft - Google Patents

Behandling av kreft

Info

Publication number: NO20031673L
Authority: NO; Norway
Prior art keywords: cancer; treatment; aplidine; carnitine; useful
Prior art date: 2000-10-12

Application number

NO20031673A

Other languages

English (en)

Other versions

NO20031673D0 (no

Inventor

Lazaro Luis Lopez

Jose Maria Fernandez-Sousa

Jean-Pierre Armand

Eric Raymond

Original Assignee

Ruffles Graham Keith

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-12

Filing date

2003-04-11

Publication date

2003-06-12

2000-10-12 Priority claimed from GB0025044A external-priority patent/GB0025044D0/en

2000-10-13 Priority claimed from GB0025209A external-priority patent/GB0025209D0/en

2000-11-15 Priority claimed from PCT/GB2000/004349 external-priority patent/WO2001035974A2/en

2001-03-23 Priority claimed from GB0107373A external-priority patent/GB0107373D0/en

2001-10-12 Priority claimed from PCT/GB2001/004555 external-priority patent/WO2002030441A2/en

2003-04-11 Application filed by Ruffles Graham Keith filed Critical Ruffles Graham Keith

2003-04-11 Publication of NO20031673D0 publication Critical patent/NO20031673D0/no

2003-06-12 Publication of NO20031673L publication Critical patent/NO20031673L/no

Links

206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 abstract 2
PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 abstract 1
229960004203 carnitine Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
210000003205 muscle Anatomy 0.000 abstract 1
229950008499 plitidepsin Drugs 0.000 abstract 1
108010049948 plitidepsin Proteins 0.000 abstract 1
230000001012 protector Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Steroid Compounds (AREA)

NO20031673A 2000-10-12 2003-04-11 Behandling av kreft NO20031673L (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GB0025044A GB0025044D0 (en)	2000-10-12	2000-10-12	Toxicity protection
GB0025209A GB0025209D0 (en)	2000-10-13	2000-10-13	Treatment of cancers
PCT/GB2000/004349 WO2001035974A2 (en)	1999-11-15	2000-11-15	Aplidine treatment of cancers
GB0107373A GB0107373D0 (en)	2001-03-23	2001-03-23	Aplidine
PCT/GB2001/004555 WO2002030441A2 (en)	2000-10-12	2001-10-12	Treatment of cancers by aplidine in conjunction with a myoprotector

Publications (2)

Publication Number	Publication Date
NO20031673D0 NO20031673D0 (no)	2003-04-11
NO20031673L true NO20031673L (no)	2003-06-12

Family

ID=27255931

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20031673A NO20031673L (no)	2000-10-12	2003-04-11	Behandling av kreft

Country Status (14)

Country	Link
US (1)	US7507766B2 (no)
JP (1)	JP2010031043A (no)
KR (1)	KR20030038812A (no)
CN (1)	CN1479622A (no)
AT (1)	ATE299028T1 (no)
BR (1)	BR0114604A (no)
CZ (1)	CZ2003993A3 (no)
ES (1)	ES2243555T3 (no)
HK (1)	HK1054191A1 (no)
IL (1)	IL155273A0 (no)
NO (1)	NO20031673L (no)
NZ (1)	NZ525196A (no)
PL (1)	PL361179A1 (no)
RU (1)	RU2003113210A (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ302498B6 (cs) *	1999-11-15	2011-06-15	Pharma Mar, S. A.	Farmaceutický prípravek obsahující aplidin pro lécení rakovinových onemocnení
EP1620117A4 (en) *	2003-03-12	2009-07-29	Pharma Mar Sa	IMPROVED ANTITUMORAL TREATMENTS
EP1942944A2 (en) *	2005-10-31	2008-07-16	Genentech, Inc.	Macrocyclic depsipeptide antibody-drug conjugates and methods
WO2007101235A2 (en) *	2006-02-28	2007-09-07	Pharma Mar, S.A.	Improved antitumoral treatments
AU2008313627A1 (en) *	2007-10-19	2009-04-23	Pharma Mar, S.A.	Improved antitumoral treatments
CA2717409A1 (en) *	2008-03-07	2009-09-11	Pharma Mar, S.A.	Improved anticancer treatments
JP2014516075A (ja)	2011-06-06	2014-07-07	シェブロンフィリップスケミカルカンパニーエルピー	癌治療のためのメタロセン化合物の使用
KR102491180B1 (ko)	2017-04-27	2023-01-20	파르마 마르 에스.에이.	항종양 화합물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3161556D1 (en)	1980-09-12	1984-01-05	Univ Illinois	Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4493796A (en)	1980-09-12	1985-01-15	Board Of Trustees, Univ. Of Ill.	Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en)	1980-09-12	1990-08-21	University Of Illinois	Didemnins and nordidemnins
IT1153974B (it)	1982-09-23	1987-01-21	Erba Farmitalia	Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en)	1989-04-10	1990-08-14	The Board Of Trustees Of The University Of Illinois	Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en)	1989-09-29	1989-11-15	Pharma Mar Sa	Novel anti-viral and cytotoxic agent
DE4120327A1 (de)	1991-06-20	1992-12-24	Basf Ag	Neue peptide, ihre herstellung und verwendung
US5462726A (en)	1993-12-17	1995-10-31	Bristol-Myers Squibb Company	Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5861439A (en)	1994-11-14	1999-01-19	Alza Corporation	Method for enhanced electrotransport agent delivery
ES2102322B1 (es)	1995-07-13	1998-03-01	Pharma Mar Sa	Procedimiento de preparacion de didemnina a.
ES2151277T3 (es)	1996-05-22	2000-12-16	Protarga Inc	Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US6156724A (en)	1996-06-07	2000-12-05	Rinehart; Kenneth L.	Uses of didemnins as immunomodulating agents
EP0918693B1 (en)	1996-07-03	2001-11-07	C G Paxton Limited	Containers
DE69735583T2 (de)	1996-10-24	2007-04-05	The Board Of Trustees Of The University Of Illinois, Urbana	Semisynthetisches verfahren zur herstellung von didemninanalogen
US6380156B1 (en)	1996-10-24	2002-04-30	The Board Of Trustees Of The University Of Illnois	Total synthesis of the amino hip analogue of didemnin A
US6034058A (en)	1997-04-15	2000-03-07	Rinehart; Kenneth L.	Semi-synthetic alanyl dilemnin analogs
US6030943A (en)	1997-05-07	2000-02-29	Crumb; William J.	Dehydrodidemnin B as an L-type calcium channel enhancer
GB9803448D0 (en)	1998-02-18	1998-04-15	Pharma Mar Sa	Pharmaceutical formulation
CA2338638C (en)	1998-07-30	2009-03-17	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
US20010021380A1 (en)	1999-04-19	2001-09-13	Pluenneke John D.	Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en)	1999-05-25	2005-05-10	Point Therapeutics, Inc.	Anti-tumor agents
AU781897B2 (en)	1999-05-25	2005-06-23	Point Therapeutics, Inc.	Anti-tumor comprising boroproline compounds
CZ302498B6 (cs)	1999-11-15	2011-06-15	Pharma Mar, S. A.	Farmaceutický prípravek obsahující aplidin pro lécení rakovinových onemocnení
CA2405779A1 (en)	2000-04-07	2001-10-18	The Trustees Of The University Of Pennsylvania	Tamandarin and didemnin analogs and methods of making and using them
US6509315B1 (en)	2000-04-07	2003-01-21	The Trustees Of The University Of Pennsylvania	Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk)	2000-06-30	2006-09-15	Фарма Мар, С.А.	Протипухлинні похідні аплідину
AU1305302A (en)	2000-10-05	2002-04-15	Immunex Corp	Nectin polypeptides, polynucleotides, methods of making and use thereof
MXPA03003230A (es)	2000-10-12	2004-12-03	Pharma Mar Sa	Tratamiento de canceres.
WO2002032374A2 (en)	2000-10-18	2002-04-25	Immunex Corporation	Methods for treating il-18 mediated disorders
DE60229414D1 (de)	2001-10-19	2008-11-27	Pharma Mar Sa	Verwendung von aplidine in der behandlung von pankreaskrebs
EP1620117A4 (en)	2003-03-12	2009-07-29	Pharma Mar Sa	IMPROVED ANTITUMORAL TREATMENTS

2001
- 2001-10-12 IL IL15527301A patent/IL155273A0/xx unknown
- 2001-10-12 PL PL01361179A patent/PL361179A1/xx not_active Application Discontinuation
- 2001-10-12 ES ES01974510T patent/ES2243555T3/es not_active Expired - Lifetime
- 2001-10-12 CN CNA018204740A patent/CN1479622A/zh active Pending
- 2001-10-12 NZ NZ525196A patent/NZ525196A/en unknown
- 2001-10-12 HK HK03106440.0A patent/HK1054191A1/zh unknown
- 2001-10-12 AT AT01974510T patent/ATE299028T1/de not_active IP Right Cessation
- 2001-10-12 US US10/398,835 patent/US7507766B2/en not_active Expired - Fee Related
- 2001-10-12 RU RU2003113210/14A patent/RU2003113210A/ru not_active Application Discontinuation
- 2001-10-12 CZ CZ2003993A patent/CZ2003993A3/cs unknown
- 2001-10-12 KR KR10-2003-7005081A patent/KR20030038812A/ko not_active Withdrawn
- 2001-10-12 BR BR0114604-1A patent/BR0114604A/pt not_active IP Right Cessation
2003
- 2003-04-11 NO NO20031673A patent/NO20031673L/no not_active Application Discontinuation
2009
- 2009-11-06 JP JP2009255266A patent/JP2010031043A/ja active Pending

Also Published As

Publication number	Publication date
IL155273A0 (en)	2003-11-23
ATE299028T1 (de)	2005-07-15
US20040010043A1 (en)	2004-01-15
CN1479622A (zh)	2004-03-03
JP2010031043A (ja)	2010-02-12
ES2243555T3 (es)	2005-12-01
US7507766B2 (en)	2009-03-24
PL361179A1 (en)	2004-09-20
RU2003113210A (ru)	2004-11-27
CZ2003993A3 (cs)	2004-02-18
HK1054191A1 (zh)	2003-11-21
BR0114604A (pt)	2003-10-14
KR20030038812A (ko)	2003-05-16
NO20031673D0 (no)	2003-04-11
NZ525196A (en)	2004-09-24

Legal Events

Date	Code	Title	Description
2011-05-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20024610D0 (no)	2002-09-26	Synergistiske metoder og blandinger for behandling av kreft
HN2001000244A (es)	2003-11-07	Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
EA200501251A1 (ru)	2008-12-30	Антинеопластические комбинации
EP1478406A4 (en)	2006-01-11	COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS AND OTHER MATERIALS AND METHOD FOR THE PRODUCTION AND USE THEREOF
DE69907977D1 (de)	2003-06-18	Pyrrolobenzodiazepine
HN2001000243A (es)	2002-11-07	Inhibidores de metaloproteinasa del tipo pirimidin - 2, 4, 6 - triona
CY1108610T1 (el)	2014-04-09	Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
EP1240280A4 (en)	2010-11-17	PROCESS FOR TREATING COAL
PT1235571E (pt)	2004-12-31	Utilizacao de melatonina para o tratamento da alopecia androgenetica e difusa do tipo feminino
IS6575A (is)	2002-09-30	Hýdroxýfenýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
TR200103819T2 (tr)	2002-04-22	kanser tedavisinde ET743 terkipleri ve kullanımları
NO994274D0 (no)	1999-09-02	Sammensetninger til Õ behandle tumörer inneholdende haibruskekstrakter og antineoplastiske forbindelser
DK1237549T3 (da)	2004-06-07	Lipoxin A4 og dets analoger til behandling af törre öjne
SE9802208D0 (sv)	1998-06-22	Novel compounds
NO20031860L (no)	2003-06-30	Kahalalid F
DK1294372T3 (da)	2005-09-19	Törpulverformulering der omdanner racecadotril
NO20031673D0 (no)	2003-04-11	Behandling av kreft
ATE516027T1 (de)	2011-07-15	Orazamid orotat zur vorbeugung von leberschäden
FI20000635A0 (fi)	2000-03-17	COMT-inhibiittoreiden käyttö analgeettina
ATE275143T1 (de)	2004-09-15	Verbindungen
IS6563A (is)	2002-09-24	Hýdroxýfenýl-píperasinýl-metýl-bensamíðafleiður til að meðhöndla sársauka
IS6574A (is)	2002-09-30	Kínólinýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
EE200300129A (et)	2003-06-16	Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
UY26085A1 (es)	2000-10-31	N-[-(4-aminofenil)-2,3-dihidro-1,4-benzodioxina-2-metanamina su preparacion y su aplicacion en terapeutica
TR200302134T4 (tr)	2004-01-21	2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.